VS 5584

Drug Profile

VS 5584

Alternative Names: SB-2312; SB-2343; VS-5584

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator S*BIO
  • Developer Verastem
  • Class Antineoplastics; Morpholines; Purines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Mesothelioma; Solid tumours

Most Recent Events

  • 01 Dec 2016 Verastem terminates a phase I trial in Solid tumours and Lymphoma (Late-stage disease, Metastatic disease) in USA due to lack of recruitment and the company's decision to de-prioritise VS 5584 development (PO) (NCT01991938)
  • 01 Oct 2015 Verastem terminates a phase I trial in Mesothelioma (Second-line therapy or greater, Combination therapy) in USA and United Kingdom (PO) (NCT02372227)
  • 12 Feb 2015 VS 5584 receives Orphan Drug status for Mesothelioma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top